Dr. Kerry B. Goralski, PhD
Professor, College of Pharmacy, Faculty of Health Professions, Dalhousie University (primary appointment); Cross-Appointment, Department of Pharmacology, Faculty of Medicine, Dalhousie University; Cross Appointment, Department of Pediatrics, Faculty of Medicine, Dalhousie University; Affiliated Research Staff, Pediatrics – Hematology/Oncology, IWK Health Centre; President, Canadian Society of Pharmacology and Therapeutics
Dalhousie University and IWK Health Centre
Pharmacokinetics, personalized medicine, pharmacogenomics, chemotherapy, breast cancer, childhood cancers, cell culture, clinical research, animal research, pharmacology, drug resistance, drug metabolism, drug transport, adverse drug responses
I am researching the pharmacology of a group of natural product molecules called jadomycins with the goal of determining their usefulness in treating drug-resistant metastatic breast cancer. My second research area is pharmacogenomics and precision medicine, which aims to identify genetic biomarkers of severe adverse drug responses (ADRs) in children receiving chemotherapies, with the goal improving treatments and preventing ADRs. My third research area focuses on the function of the fat tissue hormone chemerin and its receptors CMKLR1 and GPR1 in obesity-associated cancers, with the goal of determining if this signaling pathway can be targeted in new cancer therapies.
Hometown: Winnipeg, Manitoba
What brought you to your current institution? I came to Dalhousie University in 1999 to complete a Post-Doctoral Fellowship with Dr. Ken Renton in the Department of Pharmacology, which ultimately led to a Faculty Position in Pharmacokinetics (my dream job) in the College of Pharmacy, where I remain today.
Learn More about my research: https://www.dal.ca/faculty/health/pharmacy/faculty-staff/faculty/graduate-faculty/kerry-goralski.html
Involvement with BHCRI to date:I have been an Associate Member of the BHCRI from 2013-2019 and have just recently been approved for Senior Scientist membership. I have supervised 4 CRTP graduate trainees and 2 undergraduate students funded through the BHCRI. I served as a member of the CRTP Scientific Review Committee from 2014-2018 and have attended and served as a poster judge at the 2014, 2016 and 2018 BHCRI Cancer Research Conferences.
Contact:College of Pharmacy, Dalhousie University, 5968 College Street, Halifax, Nova Scotia, Canada, B3H 4R2
Robertson, A.W., MacLeod, J.M., MacIntyre, L.W., Forget, S.M., Hall, S.R., Bennett, L.G., Correa, H., Kerr, R.G., Goralski, K.B. & Jakeman, D.L. Post Polyketide Synthase Carbon-Carbon Bond Formation in Type-II PKS-Derived Natural Products from Streptomyces venezuelae. J Org Chem 83, 1876-1890 (2018).
Hall, S.R. & Goralski, K.B. ZATT, TDP2, and SUMO2: breaking the tie that binds TOP2 to DNA. Translational Cancer Research 7, S439-S444 (2018).
Forget, S.M., Robertson, A.W., Hall, S.R., MacLeod, J.M., Overy, D.P., Kerr, R.G., Goralski, K.B. & Jakeman, D.L. Isolation of a jadomycin incorporating L-ornithine, analysis of antimicrobial activity and jadomycin reactive oxygen species (ROS) generation in MDA-MB-231 breast cancer cells. J Antibiot (Tokyo) 71, 722-730 (2018).
Hall, S.R., Toulany, J., Bennett, L.G., Martinez-Farina, C.F., Robertson, A.W., Jakeman, D.L. & Goralski, K.B. Jadomycins Inhibit Type II Topoisomerases and Promote DNA Damage and Apoptosis in Multidrug-Resistant Triple-Negative Breast Cancer Cells. J Pharmacol Exp Ther 363, 196-210 (2017).
Hall, S.R., Blundon, H.L., Ladda, M.A., Robertson, A.W., Martinez-Farina, C.F., Jakeman, D.L. & Goralski, K.B. Jadomycin breast cancer cytotoxicity is mediated by a copper-dependent, reactive oxygen species-inducing mechanism. Pharmacol Res Perspect 3, e00110 (2015).
Issa, M.E., Hall, S.R., Dupuis, S.N., Graham, C.L., Jakeman, D.L. & Goralski, K.B. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells. Anticancer Drugs 25, 255-269 (2014).
Dupuis, S.N., Robertson, A.W., Veinot, T., Monro, S.M.A., Douglas, S.E., Syvitski, R.T., Goralski, K.B., McFarland, S.A. & Jakeman, D.L. Synthetic diversification of natural products: semi-synthesis and evaluation of triazole jadomycins. Chemical Science 3, 1640-1644 (2012).